• Je něco špatně v tomto záznamu ?

The transcription factor GLI2 as a downstream mediator of transforming growth factor-β-induced fibroblast activation in SSc

R. Liang, B. Šumová, C. Cordazzo, T. Mallano, Y. Zhang, T. Wohlfahrt, C. Dees, A. Ramming, D. Krasowska, M. Michalska-Jakubus, O. Distler, G. Schett, L. Šenolt, JH. Distler,

. 2017 ; 76 (4) : 756-764. [pub] 20161028

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17023557
E-zdroje Online Plný text

NLK ProQuest Central od 1939-01-01 do Před 6 měsíci
Health & Medicine (ProQuest) od 1939-01-01 do Před 6 měsíci
Family Health Database (ProQuest) od 1939-01-01 do Před 6 měsíci

OBJECTIVES: Hedgehog signalling plays a critical role during the pathogenesis of fibrosis in systemic sclerosis (SSc). Besides canonical hedgehog signalling with smoothened (SMO)-dependent activation of GLI transcription factors, GLI can be activated independently of classical hedgehog ligands and receptors (so-called non-canonical pathways). Here, we aimed to evaluate the role of non-canonical hedgehog signalling in SSc and to test the efficacy of direct GLI inhibitors that target simultaneously canonical and non-canonical hedgehog pathways. METHODS: The GLI inhibitor GANT-61 was used to inhibit canonical as well as non-canonical hedgehog signalling, while the SMO inhibitor vismodegib was used to selectively target canonical hedgehog signalling. Furthermore, GLI2 was selectively depleted in fibroblasts using the Cre-LoxP system. The effects of pharmacological or genetic of GLI2 on transforming growth factor-β (TGF-β) signalling were analysed in cultured fibroblasts, in bleomycin-induced pulmonary fibrosis and in mice with overexpression of a constitutively active TGF-β receptor I. RESULTS: TGF-β upregulated GLI2 in a Smad3-dependent manner and induced nuclear accumulation and DNA binding of GLI2. Fibroblast-specific knockout of GLI2 protected mice from TBR(act)-induced fibrosis. Combined targeting of canonical and non-canonical hedgehog signalling with direct GLI inhibitors exerted more potent antifibrotic effects than selective targeting of canonical hedgehog signalling with SMO inhibitors in experimental dermal and pulmonary fibrosis. CONCLUSIONS: Our data demonstrate that hedgehog pathways and TGF-β signalling both converge to GLI2 and that GLI2 integrates those signalling to promote tissue fibrosis. These findings may have translational implications as non-selective inhibitors of GLI2 are in clinical use and selective molecules are currently in development.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023557
003      
CZ-PrNML
005      
20170720123536.0
007      
ta
008      
170720s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/annrheumdis-2016-209698 $2 doi
035    __
$a (PubMed)27793816
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Liang, Ruifang $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
245    14
$a The transcription factor GLI2 as a downstream mediator of transforming growth factor-β-induced fibroblast activation in SSc / $c R. Liang, B. Šumová, C. Cordazzo, T. Mallano, Y. Zhang, T. Wohlfahrt, C. Dees, A. Ramming, D. Krasowska, M. Michalska-Jakubus, O. Distler, G. Schett, L. Šenolt, JH. Distler,
520    9_
$a OBJECTIVES: Hedgehog signalling plays a critical role during the pathogenesis of fibrosis in systemic sclerosis (SSc). Besides canonical hedgehog signalling with smoothened (SMO)-dependent activation of GLI transcription factors, GLI can be activated independently of classical hedgehog ligands and receptors (so-called non-canonical pathways). Here, we aimed to evaluate the role of non-canonical hedgehog signalling in SSc and to test the efficacy of direct GLI inhibitors that target simultaneously canonical and non-canonical hedgehog pathways. METHODS: The GLI inhibitor GANT-61 was used to inhibit canonical as well as non-canonical hedgehog signalling, while the SMO inhibitor vismodegib was used to selectively target canonical hedgehog signalling. Furthermore, GLI2 was selectively depleted in fibroblasts using the Cre-LoxP system. The effects of pharmacological or genetic of GLI2 on transforming growth factor-β (TGF-β) signalling were analysed in cultured fibroblasts, in bleomycin-induced pulmonary fibrosis and in mice with overexpression of a constitutively active TGF-β receptor I. RESULTS: TGF-β upregulated GLI2 in a Smad3-dependent manner and induced nuclear accumulation and DNA binding of GLI2. Fibroblast-specific knockout of GLI2 protected mice from TBR(act)-induced fibrosis. Combined targeting of canonical and non-canonical hedgehog signalling with direct GLI inhibitors exerted more potent antifibrotic effects than selective targeting of canonical hedgehog signalling with SMO inhibitors in experimental dermal and pulmonary fibrosis. CONCLUSIONS: Our data demonstrate that hedgehog pathways and TGF-β signalling both converge to GLI2 and that GLI2 integrates those signalling to promote tissue fibrosis. These findings may have translational implications as non-selective inhibitors of GLI2 are in clinical use and selective molecules are currently in development.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a anilidy $x farmakologie $7 D000813
650    _2
$a zvířata $7 D000818
650    _2
$a kultivované buňky $7 D002478
650    _2
$a kolagen typu I $x genetika $7 D024042
650    _2
$a růstový faktor pojivové tkáně $x genetika $7 D055513
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fibroblasty $x účinky léků $x metabolismus $7 D005347
650    _2
$a fibróza $7 D005355
650    _2
$a genový knockout $7 D055786
650    _2
$a proteiny hedgehog $x metabolismus $7 D053823
650    _2
$a lidé $7 D006801
650    _2
$a transkripční faktory Krüppel-like $x antagonisté a inhibitory $x genetika $x metabolismus $7 D051741
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a myši knockoutované $7 D018345
650    _2
$a myši transgenní $7 D008822
650    _2
$a lidé středního věku $7 D008875
650    _2
$a inhibitor aktivátoru plazminogenu 1 $x genetika $7 D017395
650    _2
$a protein-serin-threoninkinasy $x antagonisté a inhibitory $x genetika $7 D017346
650    _2
$a pteridiny $x farmakologie $7 D011621
650    _2
$a plicní fibróza $x chemicky indukované $x metabolismus $7 D011658
650    _2
$a pyridiny $x farmakologie $7 D011725
650    _2
$a pyrimidiny $x farmakologie $7 D011743
650    _2
$a messenger RNA $x metabolismus $7 D012333
650    _2
$a receptory transformujícího růstového faktoru beta $x antagonisté a inhibitory $x genetika $7 D018125
650    _2
$a rekombinantní proteiny $x farmakologie $7 D011994
650    _2
$a systémová sklerodermie $x genetika $x metabolismus $7 D012595
650    _2
$a signální transdukce $x účinky léků $7 D015398
650    _2
$a kůže $x účinky léků $x patologie $7 D012867
650    _2
$a protein Smad3 $x metabolismus $7 D051900
650    _2
$a receptor Smoothened $x antagonisté a inhibitory $7 D000072086
650    _2
$a transformující růstový faktor beta $x metabolismus $x farmakologie $7 D016212
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Šumová, Barbora $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany. Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Institute of Rheumatology, Charles University, Prague, Czech Republic.
700    1_
$a Cordazzo, Cinzia $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany. Dipartimento Cardiotoracico e Vascolare, Laboratory of Respiratory Cell Biology, University of Pisa, Pisa, Italy.
700    1_
$a Mallano, Tatjana $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Zhang, Yun $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Wohlfahrt, Thomas $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Dees, Clara $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Ramming, Andreas $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Krasowska, Dorota $u Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, Poland.
700    1_
$a Michalska-Jakubus, Małgorzata $u Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, Poland.
700    1_
$a Distler, Oliver $u Rheumaklinik, University Hospital Zurich, Zurich, Switzerland.
700    1_
$a Schett, Georg $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Šenolt, Ladislav $u Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Institute of Rheumatology, Charles University, Prague, Czech Republic.
700    1_
$a Distler, Jörg H W $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
773    0_
$w MED00000444 $t Annals of the rheumatic diseases $x 1468-2060 $g Roč. 76, č. 4 (2017), s. 756-764
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27793816 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170720124029 $b ABA008
999    __
$a ok $b bmc $g 1239238 $s 984470
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 76 $c 4 $d 756-764 $e 20161028 $i 1468-2060 $m Annals of the rheumatic diseases $n Ann Rheum Dis $x MED00000444
LZP    __
$a Pubmed-20170720

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace